Document Detail


Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists.
MedLine Citation:
PMID:  21028996     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Lipid-lowering therapy with a statin not only powerfully lowers cholesterol but also exerts anti-inflammatory effects by decreasing serum C-reactive protein (CRP). Since an angiotensin II, type-1 receptor antagonist (ARB) also decreases CRP levels, the add-on effect of statins on CRP may be worth exploring. We determined the effect of pitavastatin on serum levels of highly sensitive CRP (hs-CRP) in 30 patients with hypercholesterolemia undergoing treatment with anti-hypertensive medication including ARBs. Pitavastatin, 2 mg daily, was given. The control group consisted of hypertensive patients without hyperlipidemia. The low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and hs-CRP were measured at baseline, 1, 3, 6, and 12 months after treatment. For the atherosclerotic index, LDL-C/HDL-C ratios at 12 months were calculated. The LDL-C level was markedly reduced at 1 month and thereafter. The baseline level of hs-CRP in the hyperlipidemia group was significantly higher than that in the control group (1.647 ± 0.210 mg/L vs. 0.666 ± 0.097 mg/L p < 0.0001). After 3 months, the percentage of reduction of hs-CRP was significantly higher than that in the control group. The absolute values of hs-CRP were significantly decreased to a level similar to the control group, and the hs-CRP in both groups was remained at the same level for 12 months. Although the LDL-C/HDL-C ratios of the pitavastatin group was significantly reduced from 3.3 to 1.8, those of the control group were not changed. In conclusion, pitavastatin was found to have powerful anti-inflammatory, add-on effects over the similar effects of ARB as assessed by hs-CRP.
Authors:
Masamichi Yoshika; Yutaka Komiyama; Midori Masuda; Toyohiko Yokoi; Hiroya Masaki; Hiroe Ohkura; Hakuo Takahashi
Related Documents :
8031206 - Comparative effects of lovastatin and niacin in primary hypercholesterolemia. a prospec...
12504826 - Simvastatin reduces nf-kappab activity in peripheral mononuclear and in plaque cells of...
11009276 - High-density lipoprotein cholesterol and triglyceride response with simvastatin versus ...
18370666 - Clinical use of a carbohydrate-restricted diet to treat the dyslipidemia of the metabol...
21473896 - In vitro and in vivo safety assessment of edible blue-green algae, nostoc commune var. ...
2408416 - Dietary treatment of nickel dermatitis.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical and experimental hypertension (New York, N.Y. : 1993)     Volume:  32     ISSN:  1525-6006     ISO Abbreviation:  Clin. Exp. Hypertens.     Publication Date:  2010  
Date Detail:
Created Date:  2010-10-29     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9305929     Medline TA:  Clin Exp Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  341-6     Citation Subset:  IM    
Affiliation:
Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Moriguchi, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differences between hypertensive and atherosclerotic lesions in retinal arteries assessed by Scheie'...
Next Document:  Plasma plasminogen activator inhibitor 1 (PAI-1) and P-selectin levels in urgent hypertension: effec...